Terns Pharmaceuticals, Inc. (TERN)
May 5, 2026 - TERN was delisted (reason: acquired by MRK)
52.95
+0.02 (0.04%)
Inactive · Last trade price on May 4, 2026

Company Description

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.

The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals logo
Country United States
Founded 2017
IPO Date Feb 5, 2021
Industry Biotechnology
Sector Healthcare
Employees 59
CEO Amy Burroughs

Contact Details

Address:
1065 East Hillsdale Boulevard, Suite 100
Foster City, California 94404
United States
Phone 650 525 5535
Website ternspharma.com

Stock Details

Ticker Symbol TERN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001831363
CUSIP Number 880881107
ISIN Number US8808811074
SIC Code 2834

Key Executives

Name Position
Amy L. Burroughs M.B.A. Chief Executive Officer and Director
Melita Sun Jung Chief Business Officer
Andrew W. Gengos Chief Financial Officer and Head of Corporate Development
Scott Harris Chief Development and Operations Officer
Caryn Gordon McDowell J.D. Chief Legal Officer
Theresa Clouser Vice President of Marketing
Robin Andrulevich Chief People Officer
Dr. Jeffrey R. Jasper Ph.D. SVice President and Senior Distinguished Research Fellow
Dr. Emil T. Kuriakose M.D. Chief Medical Officer
Debra Sieminski Senior Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
May 5, 2026 POS AM Post-Effective amendments for registration statement